Skip to main content

Drug Interactions between Bronkosol and doxepin topical

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

isoetharine doxepin topical

Applies to: Bronkosol (isoetharine) and doxepin topical

MONITOR: Concomitant use of beta-2 adrenergic agonists with tricyclic antidepressants (TCAs) may increase the risk and/or severity of cardiovascular adverse effects such as hypertension, palpitation, chest pain, and arrhythmia. In addition, both classes of drugs have been reported to produce electrocardiographic changes including flattening of the T wave and prolongation of the QTc interval, and these effects may be additive during coadministration.

MANAGEMENT: Caution is advised if beta-2 agonists are used with TCAs, or within two weeks of discontinuing the latter. Cardiovascular status should be closely monitored.

References

  1. (2002) "Product Information. Proventil (albuterol)." Schering Corporation
  2. "Product Information. Serevent (salmeterol)." Glaxo Wellcome
  3. (2001) "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals
  4. (2001) "Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim
  5. (2022) "Product Information. Tornalate (bitolterol)." Apothecon Inc
  6. (2001) "Product Information. Xopenex (levalbuterol)." Sepracor Inc
  7. (2001) "Product Information. Foradil (formoterol)." Novartis Pharmaceuticals
  8. (2006) "Product Information. Brovana (arformoterol)." Sepracor Inc
  9. (2011) "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals
  10. (2013) "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline
  11. (2014) "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim
View all 11 references

Switch to consumer interaction data

Drug and food interactions

Moderate

isoetharine food

Applies to: Bronkosol (isoetharine)

MONITOR: Coadministration of two or more sympathomimetic agents may increase the risk of adverse effects such as nervousness, irritability, and increased heart rate. Central nervous system (CNS) stimulants, particularly amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.

MANAGEMENT: Caution is advised if two or more sympathomimetic agents are coadministered. Pulse and blood pressure should be closely monitored.

References

  1. Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr (1979) "Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients." Psychiatry Res, 1, p. 45-52
  2. Cavanaugh JH, Griffith JD, Oates JA (1970) "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther, 11, p. 656
  3. (2001) "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc
  4. (2001) "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals
  5. (2001) "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals
  6. (2001) "Product Information. Focalin (dexmethylphenidate)." Mikart Inc
  7. (2002) "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company
View all 7 references

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer